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Abstract
Background: Although cigarette smoking is the principal cause of lung carcinogenesis, chronic obstructive
pulmonary disease (COPD), an inflammatory disease of the lung, has been identified as an independent risk factor
for lung cancer. Bacterial colonization, particularly with non-typeable Haemophilus influenzae (NTHi), has been
implicated as a cause of airway inflammation in COPD besides cigarette smoke. Accordingly, we hypothesized that
lung cancer promotion may occur in a chronic inflammatory environment in the absence of concurrent carcinogen
exposure.
Results: Herein, we investigated the effects of bacterial-induced COPD-like inflammation and tobacco carcinogen-
enhanced tumorigenesis/inflammation in the retinoic acid inducible G protein coupled receptor knock out mouse
model (Gprc5a-/- mouse) characterized by late-onset, low multiplicity tumor formation. Three-month-old Gprc5a-/-
mice received 4 intraperitoneal injections of the tobacco-specific carcinogen, NNK, followed by weekly exposure to
aerosolized NTHi lysate for 6 months. The numbers of inflammatory cells in the lungs and levels of several
inflammatory mediators were increased in Gprc5a-/- mice treated with NTHi alone, and even more so in mice
pretreated with NNK followed by NTHi. The incidence of spontaneous lung lesions in the Gprc5a-/- mice was low,
but NTHi exposure led to enhanced development of hyperplastic lesions. Gprc5a-/- mice exposed to NNK alone
developed multiple lung tumors, while NTHi exposure increased the number of hyperplastic foci 6-fold and the
tumor multiplicity 2-fold. This was associated with increased microvessel density and HIF-1a expression.
Conclusion: We conclude that chronic extrinsic lung inflammation induced by bacteria alone or in combination
with NNK enhances lung tumorigenesis in Gprc5a-/- mice.
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Background
Worldwide, lung cancer remains the leading cause of
cancer death in both men and women, even though an
extensive list of modifiable risk factors has long been
identified [1]. Cigarette smoking is the principal cause
of lung carcinogenesis [2]. However several studies have
found that smokers with chronic obstructive pulmonary
disease (COPD) have an increased risk of lung cancer (3
to 10 fold) compared to smokers with comparable cigar-
ette exposure but without COPD [3,4]. It has also been
shown that increased lung cancer mortality is associated
with a history of COPD, even among persons who had
never been active smokers [5].
The pooled global prevalence of COPD in adults 40
years or older is 9%, and it is a leading cause of morbid-
ity and mortality in the United States [6]. Histopatholo-
gic studies have clearly demonstrated lung inflammation
in COPD [7]. Smoking also causes most cases of COPD
[8], however, among smokers with COPD, inflammation
persists and lung function continues to deteriorate even
following withdrawal of cigarette smoke [8]. These facts
suggest that the later phase of lung carcinogenesis may
occur in a chronic inflammatory environment in the
absence of concurrent carcinogen exposure.
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model of airway inflammation induced by repetitive
exposure to an aerosolized lysate of non-typeable Hae-
mophilus influenzae (NTHi) [9]. NTHi is the most com-
mon bacterial colonizer of airways in COPD patients
[10,11], present in the airways of 30% of COPD patients
measured at a single point in time, and in more than
50% of COPD patients followed longitudinally [12]. We
have shown that NTHi-induced COPD-like inflamma-
tion enhances lung tumorigenesis in a mouse model of
lung cancer induced by airway epithelial expression of
an oncogene (K-ras) [13]. Importantly, we and others
have shown that there is a clear specificity for the nat-
ure of inflammation in lung cancer promotion, because
induction of asthma-like (Th2 type) airway inflammation
using weekly exposure to ovalbumin (OVA) aerosol in
the same K-ras mutant mouse model [14] or in the
urethane-induced lung cancer mouse model [15] did not
result in a significant difference in lung surface tumor
number.
Because tobacco smoking is a major cause of lung
cancer, and smokers with COPD have the highest risk
of lung cancer, it is also important to define how bacter-
ial-induced COPD-like airway inflammation and tobacco
carcinogen exposure alter lung tumorigenesis in mice.
In the current study we have addressed this question
using a tobacco-specific carcinogen exposure followed
by an NTHi exposure in a newly developed genetic
mouse model of lung cancer induced by lack of a tumor
suppressor gene. This mouse model is based on the
knockout of the retinoic acid inducible G protein
coupled receptor Gprc5a gene, which leads to late-
onset, low multiplicity lung tumor formation as pre-
viously described [16]. This differs substantially from the
m o d e lw eh a v eu s e dp r e v i o u s l y( t h eK - r a so n c o g e n e
induced mouse model of lung cancer), and better emu-
lates the typical course of lung cancer development in
the setting of COPD in humans who have smoked cigar-
ettes and become chronically colonized with bacteria.
We found that Gprc5a-/- mice treated with NTHi alone
develop chronic COPD-like inflammation and exhibit a
several fold increase in the incidence of premalignant
lesions. Furthermore, NTHi strongly enhanced lung
tumor multiplicity in mice pretreated with the tobacco
carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none (NNK).
Results
Effect of NNK and NTHi on lung inflammation
To test the role of airway inflammation in promotion of
lung tumorigenesis, we exposed Gprc5a-/- mice to 4
weekly intraperitoneal (i.p.) injections of NNK from the
age of 10 to 14 weeks, or to weekly NTHi lysate aerosol
once weekly for 20 weeks starting at age 6 months, or
to NNK followed by NTHi (Figure 1). Analysis of
bronchoalveolar lavage fluid (BALF) collected from
these mice showed that exposure to NNK alone resulted
in a slight rise in the numbers of macrophages and neu-
trophils, while exposure to NTHi alone resulted in a
marked influx of neutrophils, macrophages, and lympho-
cytes, with total leukocyte numbers increasing 7-fold
(Figure 2A). Notably, the sequential exposure to NNK
and NTHi increased even further the infiltration of
inflammatory cells into the lung (Figure 2A). Histologic
analysis of inflammation in lung tissue demonstrated
that while the control group of Gprc5a-/- mice showed
almost no inflammation, progressive increases in inflam-
mation were observed in the groups treated with NNK
only, NTHi only, and NNK followed by NTHi (Figure
2B).
Leukocyte recruitment in mice exposed to NNK,
NTHi, or NNK/NTHi was accompanied by increases in
cytokines and chemokines in BALF (Table 1). There
were increased levels of proinflammatory cytokines (IL-
6, TNF-a,a n dI L - 1 b), IFN-g, IL-17 and neutrophil (KC,
MIP-2), monocyte (MIP-1a), and CD8 cell (MIP-1a)
chemokines. NNK alone and NTHi alone each increased
the levels of certain cytokines and chemokines, but the
greatest fold change in the level of most cytokines and
chemokines was found in the dual NNK/NTHi-exposed
group.
Effect of NNK and NTHi on lung tumor progression
The effect of NNK and NTHi alone or in combination
on lung tumor progression was analyzed by determining
the number and histological features of lesions present
on the pleural surface and in the parenchyma of the
lungs of Gprc5a-/- mice. As shown in Figure 3A, NNK
exposure lead to the development of multiple lung sur-
face lesions (23.25 ± 4.5 in NNK-exposed vs 0.38 ± 0.29
in control mice) and increased epithelial hyperplasia
(Figure 3B) and tumors (Figure 3C). In contrast, chronic
NTHi exposure alone induced minor increases in lung
s u r f a c el e s i o n s( F i g u r e3 A )a n dt u m o r s( F i g u r e3 C ) ,b u t
it did cause an increase in proliferative lesions (Figure
3B). Mice exposed sequentially to NNK and NTHi
showed a 3.5-fold increase in the multiplicity of surface
lesions compared with mice exposed to NNK only
(70.13 ± 8.28 vs 23.25 ± 4.5). Similarly, the multiplicity
of hyperplastic lesions and tumors was higher in the
NNK/NTHi than in the NNK only group by 4.5- and
2.2- fold, respectively (Figure 3B, and 3C). The incidence
of surface lesions and hyperplastic lesions was increased
in all three treatment groups compared to the untreated
controls (Figure 3A and 3B), and the incidence of hyper-
plastic lesions in Gprc5a-/- mice exposed to both NNK
and NTHi reached 100% (Figure 3B). However, NTHi
alone did not increase the incidence of tumors even
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a higher tumor incidence than mice exposed to NNK
only (Figure 3C).
All tumors were classified according to morphology
and there was a preponderance of papillary adenomas in
all groups (the highest percentage seen in NTHi, and
NTHi + NNK groups). Additional morphologic types in
the NNK + NTHi group were observed including solid
and mixed adenomas, and papillary adenocarcinoma,
but their numbers were not significant. Representative
macroscopic and microscopic histopathologic images of
lung sections from each treatment group are shown in
Figure 4. Histological examination revealed that the
lungs of untreated Gprc5a -/- mice contained almost no
tumor or hyperplastic lesion at the age of one year (Fig-
ure 4A). The lungs of Gprc5a -/- mice exposed to NNK
alone showed an average of 13 foci of bronchiolar and/
or alveolar hyperplasia, and an average of 2 adenomas
(Figure 4B). These lesions were associated with macro-
phage infiltration (Figure 4B, lower right panel). The
Figure 1 Experimental design. Gprc5a-/- mice were randomized to 4 consecutive, weekly injections of NNK or saline between the ages of 10
and 14 weeks, followed by exposure to an aerosolized UV-killed lysate of NTHi or saline between the ages of 6 and 12 months.
Figure 2 Analysis of lung inflammation. (A) Total and lineage-specific leukocyte numbers in bronchoalveolar lavage fluid (BALF) one day after
the last NTHi or saline aerosol exposure are shown (n = 4, mean ± SE, *= P < 0.05 for NTHi or NNK/NTHi-exposed Gprc5a-/- mice vs PBS or
NNK-exposed Gprc5a-/- mice). (B) Histologic grading of inflammation in lung tissue from each treatment group (n = 6, mean ± SE, *= P < 0.05
for NNK vs PBS, **= P < 0.05 for NTHi vs NNK, and ***= P < 0.05 for NNK/NTHi-exposed Gprc5a-/- mice vs NTHi-exposed Gprc5a-/- mice).
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showed an average of 5 foci of bronchiolar and/or alveo-
lar hyperplasia and 1 adenoma (Figure 4C), with infiltra-
tion of neutrophils, macrophages and lymphocytes in
the airways and alveoli. The average numbers of hyper-
plastic lesions and adenomasi n c r e a s e dt o6 1 ,a n d1 4 ,
respectively, in the lungs of Gprc5a -/- mice exposed to
both NNK and NTHi (Figure 4D). This was associated
with infiltration of neutrophils, macrophages, and lym-
phocytes (Figure 4D, lower right panel). Lymphocytes
were seen in nearly all treatment groups and the distri-
bution varied from peri-tumor, intra-tumor, perivascu-
lar, and peribronchiolar. In some cases, the anatomic
distribution of this follicular lymphoid hyperplasia was
consistent with bronchus-associated lymphoid tissue
(BALT), but clear association with one group could not
be made. BALTs were randomly distributed along the
small airways but were usually located between a
bronchiole and an artery.
Effect of NNK and NTHi on microvascular density and HIF-
1a expression
Because inflammation is often associated with angiogen-
esis [17] and angiogenesis is required for tumor promo-
tion [18], we asked whether NNK and NTHi treatments
affect microvascular density of lung lesions using the
CD105 marker. Immunohistochemical staining of lung
tissues showed enhanced CD105 expression within
hyperplasia (Figure 5B) and tumors (Figure 5D) in
NNK/NTHi-treated mice compared to NNK alone trea-
t e dm i c e( F i g .A ,a n dC ) ,i n d i cating significant increase
in microvascular density of pulmonary tumors in
response to NTHi. This was associated with hot-spots of
high stromal hypoxia inducible factor 1alpha (HIF-1a)
expression, an essential regulator of inflammation [19]
and angiogenesis [18], in tumors (Figure 5F), and high
expression in perivascular-peribronchiolar lymphocytes
(Figure 5H), suggesting activation of HIF-1a related
angiogenesis in response to NTHi-induced
inflammation.
Discussion
The likelihood of developing lung cancer within 10 years
is 3-fold greater in patients with mild to moderate
COPD and 10-fold greater in patients with severe
COPD compared to smokers with normal lung function
[4]. COPD is thought to be caused by the lung para-
nchymal response to inflammation from cigarette smoke
and bacterial colonization of smoke-injured airways
[10,20]. These epidemiologic data suggest that chronic
airway inflammation caused by tobacco smoke and
microbial infection promote lung carcinogenesis [21,22],
and that lung cancer risk is positively associated with
the severity and duration of inflammation [23]. How-
ever, while these data underlie the relationships, they do
not establish causal links which are addressed in this
study using a novel mouse model of lung carcinogenesis.
Tumor cells themselves produce various cytokines and
chemokines that attract leukocytes (intrinsic inflamma-
tion). The inflammatory component of a developing
neoplasm may include a diverse leukocyte population
including neutrophils, dendritic cells, macrophages, and
lymphocytes, all of which are capable of producing an
array of cytokines, cytotoxic mediators including reactive
oxygen species, serine and cysteine proteases, and
matrix metalloproteinases (MMPs) [24,25]. Sustained
cell proliferation in this environment rich in inflamma-
tory cells, growth factors, activated stroma, and DNA-
damage-promoting agents potentiates neoplastic risk
[ 2 4 , 2 6 ] .W eh a v ep r e v i o u s l ys h o w nt h a tt h el o s so ft h e
tumor suppressor gene Gprc5a in mouse lung epithelial
cells results in expression of various cytokines and
Table 1 Inflammatory mediators detected in BALF collected the day after the last treatment
Challenge PBS NNK NNK:PBS NTHi NTHi:PBS NNK+NTHi NNK+NTHi:PBS
Cytokines
TNF-a 13.4 ± 1.5 67.9 ± 9.5 5.1 * 59.4 ± 2.5 4.4 * 48.5 ± 5.2 3.6 *
IL-1b 4.1 ± 0.6 18.5 ± 1.2 4.5 * 21.2 ± 2.4 5.2 * 52.5 ± 4.9 12.8 *
IL-6 1.7 ± 0.4 4.1 ± 0.3 2.4 * 60.8 ± 17.5 35.7 * 128.3 ± 20.5 75.4 *
IFN-g 8.8 ± 1.4 95.2 ± 11.7 10.8 * 59.1 ± 5.4 6.7 * 36.1 ± 3.2 4.1 *
IL-17 0.4 ± 0.1 1.1 ± 0.1 2.7 * 46.9 ± 1.9 117.2 * 19.9 ± 0.3 49.7 *
Chemokines
KC 4.7 ± 1.3 8.8 ± 1.8 1.9 9.7 ± 0.4 2.1 70.9 ± 10.6 15.1 *
MIP-1a 1.3 ± 0.3 2.7 ± 1.1 2.1 7.6 ± 0.7 5.8 * 13.8 ± 2.6 10.6 *
MIP-2 12.9 ± 0.3 22.8 ± 6.8 1.7 19.3 ± 1.1 1.5 * 44.3 ± 1.7 3.4 *
Data are expressed in pg/ml and presented as the mean ± SEM (n = 3), and *= P < 0.05
BALF, bronchoalveolar lavage fluid; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; NTHi, non-typeable Haemophilus influenzae; TNF-a, tumor necrosis factor
alpha; IL-1b, interleukin 1 beta; IL-6, interleukin 6; IFN-g, interferon gamma; IL-17, interleukin 17; KC, keratinocyte-derived chemokine; MIP-1a, macrophage
inflammatory protein 1 alpha; MIP-2, macrophage inflammatory protein 2.
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Page 4 of 11Figure 3 Analysis of lung carcinogenesis.( A )L u n gs u r f a c el e s i o nn u m b e r s( l e f t )a n di n c i d ence of lesion development (right) in Gprc5a-/-
mice. (B) Number and incidence of hyperplastic lesions in the lungs of Gprc5a-/- mice. (C) Number and incidence of tumoral lesions in the
lungs of Gprc5a-/- mice. (Incidence is calculated as the percentage of mice with surface lesions, hyperplastic lesions, or tumoral lesions among
the total mice in the same study group, and presented as mean ± SE, *= P < 0.05 for NNK vs PBS, **= P < 0.05 for NTHi vs NNK, and ***= P <
0.05 for NNK/NTHi-exposed Gprc5a-/- mice vs NTHi-exposed Gprc5a-/- mice).
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cells into the lung tumor microenvironment [27].
Furthermore, increased activation of NF-Bi nt h e
Gprc5a-/- mouse lungs has been implicated in the crea-
tion of an inflammatory and proliferative microenviron-
m e n t[ 2 7 ] .M o r er e c e n t l y ,w eh a v ed e m o n s t r a t e dt h a t
exposure of the Gprc5a knockout mice to the tobacco-
specific carcinogen NNK enhances lung tumorigenesis
[28]. In the present study, we have shown that extrinsic
inflammation caused by bacterial infection and carcino-
gen exposure emulating COPD lung microenvironment,
can further promote tumorigenesis in this mouse model.
We previously showed the role of bacterial-induced
COPD-like inflammation in promotion of lung tumori-
genesis in an oncogenic K-ras induced mouse model of
lung cancer [13]. Here we showed the role of bacterial-
induced COPD-like inflammation in a background of
tobacco carcinogen exposure in lung cancer promotion
and progression in a mouse model with lack of Gprc5a
activity. Deletion of Gprc5a, which is expressed prefer-
entially in lung tissue, predisposes mice to develop
spontaneous lung tumors [16], but the tumorigenesis
process in the Gprc5a-/- mouse takes 1 to 2 years with
low multiplicity. Even with exposure to NNK [28], the
time to tumor development is slow (12 months). This is
in contrast with the rapid development and high
Figure 4 Gross and microscopic analysis of lungs in Gprc5a-/- mice. (A) Surface of freshly removed, formalin-filled control lungs of 12
months old Gprc5a-/- mice lacks visible lesions. Scans of H&E stained lung sections (2X) and microscopic image (10X) shows no lesion. (B) A few
surface lesions (double arrows) were seen after NNK treatment. Scans of H&E stained cross sections of NNK-treated lung (2X) and high
magnification (10X) microscopic images demonstrate the appearance of several papillary adenomas. (C) NTHi treatment led to perivascular and
peribronchiolar lymphocyte infiltration (**) and characteristic alveolar accumulation of acidophilic macrophages, often resulting in confluent areas
of acidophil macrophage pneumonia (AMP, #). AMP strongly co-localized with the widespread appearance of NTHi-induced premalignant,
hyperplastic lesions (10X). (D) NNK+NTHi combined treatment led to confluent lesions on the lung surface (double arrows). A high number of
pulmonary adenomas and areas of AMP are seen on the H&E scans (2X). Pulmonary hyperplasia with co-localized acidophilic macrophages (#)
and papillary adenocarcinomas (***) with surrounding of heavy inflammatory infiltration characterized by the accumulation of macrophages and
lymphocytes are seen on the microscopic images (10X, scale bar = 100 μm).
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hyperplastic (B) and tumoral lesions (D) of NNK/NTHi treated mice compared to the NNK treated mice (A, and C) detected by CD105
immunostaining (10X, scale bar = 100 μm). HIF-1a immunostaining after NNK/NTHi combined treatment showed hot-spots of high stromal
expression in tumors (F), and high expression in perivascular-peribronchiolar lymphocytes (H). In contrast, low, homogenous expression of HIF-1a
was detected in the tumors (E) and perivascular-peribronchiolar lymphocytes (G) of NNK treated mice (40X, scale bar = 25 μm).
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[13]. Therefore, the Gprc5a knockout mouse model
emulates better the typical course of lung cancer devel-
opment in the setting of COPD in humans who have
smoked cigarette and became chronically colonized with
bacteria.
Cigarette smoke contains ~4,000 chemicals, of which
~60 have been identified as carcinogens [29]. Of these
NNK is the most potent carcinogen in laboratory ani-
mals and has therefore been implicated as a significant
cause of tobacco-associated cancers including lung can-
cer [29]. Activating mutations of K-ras, which are found
in 30%-50% of lung adenocarcinoma (AC), are one of
the most common genetic alterations associated with
tobacco exposure [30]. Within days after NNK adminis-
tration, K-ras becomes mutated and activated in alveolar
type II pneumocytes and bronchiolar Clara cells, the
putative cells from which lung AC originate [31,32].
However, in the present study, we showed that NNK
exposure of Gprc5a knockout mice also results in
increased levels of inflammatory mediators and recruit-
ment of inflammatory cells into the lungs, which leads
to lung tumor promotion. This is in agreement with the
recent finding of a lung cancer promoting effect for
smoke-induced inflammation independent of its direct
mutagenesis effect in a K-ras mutant mouse model [33].
Chronic NTHi exposure in Gprc5a-/- mice resulted in
increased levels of inflammatory mediators followed by
recruitment of inflammatory cells into the lungs
(COPD-like inflammation) and lung cancer promotion,
s i m i l a rt ow h a tw eh a v ep r e v i o u s l yd e s c r i b e di no u rK -
ras induced mouse model [13]. The highest levels of
inflammation and tumor promotion were seen in
Gprc5a-/- mice exposed to both NNK and NTHi, indi-
cating an additive role for smoke- and bacterial-induced
inflammation in progression from COPD to lung cancer.
Sustained angiogenesis is one of the hallmarks of can-
cer [34], and it is required for tumor promotion. We
have also found increased microvessel density in
response to NTHi-induced inflammation. This was asso-
ciated with increased expression of HIF-1a which con-
trols inflammation [19], and activates the transcription
of genes involved in crucial aspects of cancer biology,
including angiogenesis [18]. NF-B is a critical tran-
scriptional activator of HIF-1a activity and is required
for HIF-1a protein accumulation during hypoxia
[35-37]. Activation of NF-B, a hallmark of inflamma-
tory responses, is frequently detected in COPD patients
[38], smokers [39] and tumors [40]. NF-Bi se s s e n t i a l
for promoting inflammation-associated cancers, and its
inactivation decreases tumor multiplicity and delays can-
cer progression [41-43]. In the lung there are also a lim-
ited number of studies which show that NF-B
inhibition suppresses lung cancer in mouse [44,45]. We
have previously found NF-B activation in the lungs of
wild type (WT) mice [9], Gprc5a-/- mice [27], and in
mice with mutant K-ras exposed to NTHi [13,46]. We
have also shown increased level of HIF-1a transcript in
gene expression analysis of whole lung from WT, and
mutant K-ras mice after NTHi exposure [14]. In this
study, we found that a single exposure to aerosolized
NTHi was sufficient to increase NF-B activation five-
fold in the lung of WT and Gprc5a-/- mice (data not
shown), along with increased expression of HIF-1a (Fig-
ure 5). All together these data suggest a role for NF-B
in lung cancer promotion in the Gprc5a-/- mice in
response to bacterial induced inflammation through
activation of the HIF-1a pathway and its downstream
angiogenic signals.
One of the events downstream of NF-B activation is
production of various cytokines and chemokines (e.g.
IL-6, and IL-17) that attract leukocytes [41], which
results in enhanced tumor progression, cancer cell
growth and spread, angiogenesis, invasion and tumor
immunosuppression [24,25]. We have found significantly
increased level of IL-6 and IL-17 in BALF after NTHi
exposure alone or in combination with NNK treatment
(table 1). We have previously shown an essential role for
IL-6 in promotion of lung cancer by airway inflamma-
tion [14]. IL-6 is required for differentiation of Th17
cells from naïve T cells, which mainly produce IL-17
[47,48]. IL-17 binds to the IL-17 receptor (IL-17R), and
IL-17R signaling is required for lung CXC chemokine
expression and neutrophil recruitment [49]. In addition
to the traditional T helper 1 (Th1) response (IFN-g)i n
COPD, recent developments in cytokine biology imply
that COPD might be better explained by the Th17 phe-
notype [50,51]. These are consistent with our finding
after inducing COPD-like inflammation by NTHi expo-
sure (table 1 and Figure 2A). NNK exposure may induce
at y p eo fi m m u n er e s p o n s e( Tr e g u l a t o r yr e s p o n s e )
which suppresses the anti-tumoral immune response
(CD8 T cell, and Th1 responses) and meanwhile bal-
ances the Th17 response toward an effective pro-
tumoral response.
During immune responses, neutrophils are among the
first cells to arrive at sites of inflammation. This is simi-
lar to our finding of significant neutrophil recruitment
after NTHi exposure in Gprc5a-/- mice (Figure 2A). An
increased number of tumor-associated neutrophils
(TANs) was linked to poorer outcome in patients with
bronchioloalveolar carcinoma [52]. Neutrophils were
present within the alveolar airspaces and within the
tumor parenchyma during neoplastic development in a
urethane-induced mouse model of lung cancer [53].
Using a K-ras induced mouse model, study has shown
that TANs were involved in lung tumorigenesis by the
production of elastase [54]. We have also shown an
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tion of neutrophil recruitment secondary to suppression
of neutrophil chemoattractant (KC) in our K-ras
induced lung cancer model [46].
Conclusions
In conclusion, we propose that exposure of the airway
to smoke and microbial products induces inflammation,
which promotes the development of lung cancer. This is
associated with activation of NF-B, release of inflam-
matory mediators, recruitment of innate (neutrophil,
and macrophages) and adaptive inflammatory cells, and
activation of HIF-1a mediated angiogenesis. This will
provide the basis for preclinical testing and rationally
directed chemopreventive strategies to test the efficacy
of anti-inflammatory and anti-bacterial agents targeting
these signals in preventing carcinogenesis in patients at
high risk for tumor development and early stage cancer.
Methods
Animals and treatment
Gprc5a knockout mice (Gprc5a-/- mice) were generated
in a mixed background of 129sv × C57BL/6 as pre-
viously described [16]. The mice were maintained
according to a protocol approved by the MD Anderson
Cancer Center Institutional Animal Care and Use Com-
mittee in the specific pathogen-free animal facility,
which is approved by the American Association for
Accreditation of Laboratory Animal Care and is oper-
ated in accordance with current regulations and stan-
dards of the US Department of Agriculture and the
Department of Health and Human Services. Mice were
monitored daily for evidence of disease or death. Three-
month-old Gprc5a-/- mice (n = 20) received 4 weekly i.
p. injections of NNK (104 mg/kg of body weight) (Mid-
west Research Institute, Kansas City, MO) dissolved in
saline solution (0.9% NaCl) or saline alone (n = 20), fol-
lowed by weekly inhalation of the UV-killed lysate of
NTHi (n = 10) or saline (n = 10) from the age of 6 to12
months (Figure 1). Briefly, a lysate of NTHi strain 12
was prepared as previously described [9]. The protein
concentration was adjusted to 2.5 mg/ml in phosphate
buffered saline (PBS), and the lysate was frozen in 10 ml
aliquots at -80°C. To deliver the lysate to mice by aero-
sol, a thawed aliquot was placed in an AeroMist CA-209
nebulizer (CIS-US, Bedford, MA) driven by 10 l/min of
room air supplemented with 5% CO2 for 20 minutes.
Assessment of lung tumor burden and inflammation
One day after the last NTHi exposure, animals were
euthanized by i.p. injection of a lethal dose of avertin
(Sigma-Aldrich, St. Louis, MO). Lung surface lesion
numbers were counted (any macroscopic lesion, tumoral
or non-tumoral, seen with the naked eye on the lung
surface), then the lungs were prepared for histological
analysis as described below. In some mice (n = 5), BALF
was obtained by sequentially instilling and collecting
two aliquots of 1 ml PBS through a tracheostomy can-
nula. Total leukocyte count was determined using a
hemacytometer, and cell populations were determined
after cytocentrifugation of 300 μl of BALF followed by
Wright-Giemsa staining. The remaining BALF (~1.4 ml)
was centrifuged at 1,250 × g for 10 min, and superna-
tants were collected and stored at -70°C. Cytokine con-
centrations were measured in duplicate by multiplexed
sandwich ELISA using SearchLight Proteome Arrays
(Aushon Biosystems, Billerica, MA).
Histochemistry
The tracheas of euthanized mice were cannulated with
PE-50 tubing and sutured into place. The lungs were
perfused in situ with PBS via the right cardiac ventricle,
then infused with 10% buffered formalin (Sigma-
Aldrich), removed and placed in 10% buffered formalin
for 18 h. Tissues then were transferred to 75% ethanol,
embedded in paraffin and sectioned at 5-μm thickness.
Sections were dried at 60°C for 15 min, and then were
deparaffinized. Hematoxylin and eosin (H&E) staining
was performed by incubating the tissues in Harris hema-
toxylin (Sigma-Aldrich) followed by serial eosin and
graded ethanol steps. Three H&E sections, each 600 μm
apart, were analyzed blindly by a veterinary pathologist
for proliferative lesions, tumor (adenoma + adenocarci-
noma) multiplicity, incidence, inflammatory infiltrations
and overall inflammation grade according to the recom-
mendations of the Mouse Models of Human Cancer
Consortium [55]. The severity of inflammatory lesions
of the lungs were scored from 1 to 4 as follows: grade 1
- minimal, lesions affect less than 10% of tissue; grade 2
- mild, lesions affect 10-20% of tissue; grade 3 - moder-
ate, lesions affect 21-40% of tissue; and grade 4 -
marked or severe, lesions affect 41-100% of the tissue.
Some sections (5 μm) from NNK- and NNK/NTHi-trea-
ted groups were labeled with anti-CD105 antibody (Bio-
care Medical LLC., Concord, CA) after antigen retrieval
procedure for 20 min at 95°C in Tris-EDTA buffer, pH
9.0, and HIF-1a antibody (Novus Biologicals, Littleton,
CO, USA). Slides were then incubated with secondary
antibody, exposed to horseradish peroxidase-labeled
streptavidin (Vector, Burlingame, CA), developed with
diaminobenzidine (Vector, Bu r l i n g a m e ,C A ) ,a n dc o u n -
terstained with hematoxylin (Sigma-Aldrich).
Statistical methods
Summary statistics for cell counts in BALF and tumor
counts were computed within treatment groups, and
analysis of variance with adjustment for multiple com-
parisons was performed to examine the differences
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Page 9 of 11between the mean cell counts and tumor count of the
control group and each of the NTHi and or NTHi/NNK
treatment groups. Differences were considered signifi-
cant for P < 0.05.
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